Overall, postdiscontinuation trajectories likely reflect more than biological rebound, although the relative contribution of psychological and behavioral factors remains insufficiently studied in the context of GLP-1 RA therapy
A promising pharmacological strategy to circumvent this has been made in the treatment of obesity and the metabolic syndrome, via the integration of multiple mechanisms within a single molecule [18, 69]
This suggests anxiety reduction through enhanced coping rather than fear suppression
Regular monitoring is essential, including baseline cardiovascular assessment, ongoing evaluation of symptom response, adverse effects, blood pressure, heart rate, and growth in children
The table below outlines the most common coverage criteria that state programs evaluate during prior authorization review